Please assess the completion status of the following clinical trial:

Trial Title: Human Umbilical Cord-derived Mesenchymal Stem Cells With Injectable Collagen Scaffold Transplantation for Chronic Ischemic Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, 35-65 years old.~2. Chronic coronary artery disease with coronary Stenosis detectable by percutaneous coronary intervention (PCI). Ineligibility for percutaneous revascularization, as assessed by coronary arteriography. Ineligibility for percutaneous revascularization procedures was determined by 2 expert committees: a surgical committee comprising 2 cardiovascular surgeons and a noninvasive cardiologist, and an interventional committee comprising 2 interventional cardiologists and 1 noninvasive cardiologist.~3. MRI confirmed that chronic coronary artery disease and ischemic regions.~4. Left ventricular ejection fraction (LVEF)≤40%.~5. NYHA Class II-IV.~6. No organ dysfunction for lung, liver and kidney.~7. Patients are able and willing to observe therapeutic effect and adverse events.~8. Signed informed consent.~9. Negative serum pregnancy test.~10. No coagulation dysfunction.~11. Glycated hemoglobin ≤6.5.~Exclusion Criteria:~1. Lactating or pregnant woman.~2. Ineligibility for CABG.~3. Unexplainable baseline laboratory abnormalities.~4. Sensitivity to any of the study medications.~5. Acute myocardial infarction within 1 months of enrollment in the study.~6. Patients suffering cardiovascular disease, such as aortic disease, malignant arrhythmias, congenital heart disease, intracardiac mass, moderate or severe valvular stenosis or regurgitation.~7. History of life threatening allergic or immune-mediated reaction.~8. Systemic infection or severe local infection.~9. Shock or MODS or patients cannot cooperate with doctors.~10. Severe heart, lung, liver or renal dysfunction.~11. Taking medicine that might have effect on outcomes assess.~12. Suffering HIV, Hepatitis B or Hepatitis C.~13. Participation in any clinical trial in recent three months.~14. History of mental illness or suicide risk.~15. High expectation or unrealistic demands.~16. Recently suffered a lot of radiation exposure.~17. Previous or current history of neoplasia or other comorbidity that could impact the patient's short-term survival.~18. Patients with serious complications of coronary artery disease (e.g., perforation of interventricular septum and ventricular aneurysm and mitral regurgitation due to papillary muscle dysfunction).~19. Abnormal coagulation function.~20. Patients with hemodynamic instability which may lead to serious complications.~21. Any condition that, in the judgment of the investigator, would place the patient at under risk.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- hUC-MSCs+Injectable collagen scaffold+CABG (Type: EXPERIMENTAL): None
- hUC-MSCs+CABG (Type: ACTIVE_COMPARATOR): None
- CABG (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete